Spotlight on anti-CD20

International MS Journal

Volumn 15, Issue 1, 2008, Pages 19-25

  Waubent, Emmanuelle ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

Anti CD20 monoclolnal antibody; Anti CD20 monocolnal antibody; B cells; Multiple sclerosis; Rituximab; RituximabMultiple sclerosis

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BETA INTERFERON; CD20 ANTIBODY; DIPHENHYDRAMINE; GADOLINIUM; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PARACETAMOL; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ASTHENIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPSTEIN BARR VIRUS; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; IMMUNOMODULATION; IMMUNOREGULATION; INJECTION SITE REACTION; LYMPHOCYTE COUNT; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYELOOPTIC NEUROPATHY; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS;

EID: 51649101329     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54.
2. Martin F, Chan AC. B cell immunobiology in disease - evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-496.
3. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694-706.
4. Uccelli A, Aloisi F, Pistoia V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol 2005; 26: 254-259.
5. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II restricted T lymphocytes. Annu Rev Immunol 1990; 8: 773-793.
6. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004; 101: 11064-11069.
7. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-174.
8. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 2004; 172: 3422-3427.
9. Antel JP, Bar-Or A. Do myelin antibodies predict the diagnosis of multiple sclerosis? N Engl J Med 2003; 349: 107-109.
10. Siden A. Isoelectric focusing and crossed immuno-electrofocusing of CSF immunoglobulins in MS. J Neurol 1979; 221: 39-51.
11. Andersson M, Yu M, Söderström M, Weerth S, Baig S, Solders G et al. Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. Eur J Neurol 2002; 9: 243-251.
12. O'Connor KC, Bar-Or A, Hafler DA. The neuro-immunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21: 81-92.
13. Lucchinetti CF, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
14. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43: 465-471.
15. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175.
16. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early MS. Identification and characterization of the primary demyelinating lesions. Brain 1997; 120: 1461-1483.
17. O'Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175: 1974-1982.
18. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122: 2047-2056.
19. Egg R, Reindl M, Deisenhammer F, Linington C, Bergen T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001; 7: 285-289.
20. Berger T; Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145.
21. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11: 492-494.
22. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.
23. O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60: 382-387.
24. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich C, Ransohoff RM et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-1461.
25. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
26. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optico-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
27. Stashenko, P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685.
28. Bar-Or A, Calabresi P, Arnold D, Markowitz C, Shafer S, Kasper L et al. Rituximab in relapsing remitting multiple sclerosis: A 72-week open-label, Phase I trial. Annals of Neurol (in press).
29. Hainsworth DJ, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
30. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746-1751.
31. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
32. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
33. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293.
34. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J. Rituximab reduces B cells and T cells in the cerebrospinal fluic of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63-70.
35. Monson N, Cravens P, Frohman E, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258-264.
36. Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62: 1620-1623.
37. Hauser SL, Waubant E, Arnold D, Vollmer T, Antel J, Fox R et al. For the HERMES Trial Group. B-cell depletion with an anti-CD20 Manoclonal antibody (Rituximab) reduces disease activity in relapsing remitting multiple sclerosis: Results of a placebo-controlled randomized Phase II trial. N Engl J Med 2008; 358 676-688. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing-remitting MS. Neurology 2007; 68(Suppl 1): A99.
38. Cree B, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
39. Ruhstaller TW, Ambler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin lymphoma? Ann Oncol 2000; 11: 374-375.
40. Rodriguez M, Miller D, Lennon V. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-545.
41. Niehaus A, Shi J, Grzenkowski M, et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol 2000; 48: 362-371.